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Abstract 
Glioblastoma multiforme (GBM) is the most common glial tumor of the central nervous 
system. Overall survival is less than a year in most of the cases in spite of multimodal 
treatment approaches. A 45-year-old female with histologically confirmed giant cell GBM 
was treated at our institution. Subtotal excision of the lesion situated in the right 
precentral area was performed during the initial stay in August 2005. The patient 
improved after the procedure with no hypertension and additional neurological deficit. 
Radiotherapy plus concomitant and adjuvant temozolomide was performed. The patient 
was symptom-free for 35 months after initial surgery. From July 2008 the patient 
developed partial motor seizures in the left side of the body and progressive 
hemiparesis. Local tumor progression was demonstrated on the neuroimaging studies. In 
December 2008, a second operative intervention was performed with subtotal excision 
of the tumor. Forty-five months after the initial diagnosis the patient is still alive with 
moderate neurological deficit. Microarray analysis of the tumor found the following 
numeric chromosomal aberrations: monosomy 8, 10, 13, 22, and trisomy 21, as well as 
amplifications in 4q34.1, 4q28.2, 6q16.3, 7q36.1, 7p21.3, and deletions in 1q42.12, 
1q32.2, 1q25.2, 1p33, 2q37.2, 18q22.3, 19p13.2, Xq28, and Xq27.3. GBMs seem to be a 
heterogeneous group of glial tumors with different clinical course and therapeutic 
response. Microarray analysis is a useful method to establish a number of possible 
molecular predictors. 
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Introduction 
Glioblastoma multiforme (GBM) is the most common glial tumor of the central 
nervous system. Overall survival is less than a year in most of the cases in spite of 
multimodal treatment approaches. We describe a case of an adult female patient with 
histologically confirmed glioblastoma who survived more than 3 years after the initial 
diagnosis. 
Case Report 
A 45-year-old female was admitted at the clinic with short-term history of headache and progressive 
left-side hemiparesis (mainly of the lower limb). Magnetic resonance imaging (MRI) without contrast 
enhancement showed right-sided space-occupying lesion involving the precentral white matter adjacent 
to the midline. Marked compression of the ventricular system, perifocal edema, and imminent 
subfalcine herniation were also present (fig. 1). Subtotal excision of soft, pinkish-gray-colored, and 
moderately bleeding tumor lesion was performed by microsurgery. The patient’s headache and 
hemiparesis improved after the intervention. The histological result was glioblastoma with giant cell 
component (fig. 2). The patient underwent radiotherapy plus concomitant and adjuvant chemotherapy 
in standard regimens 1 month after the initial surgery, conventional external-beam radiotherapy with a 
total dose of 60 Gy and temozolomide. The patient was symptom-free for 35 months following initial 
surgery with no neuroimaging data of progression of the residual tumor mass (fig. 1). Since July 2008, 
the patient developed partial motor seizures and progressive hemiparesis in the left side of the body. 
Local tumor progression was found on the neuroimaging studies (fig. 1). In December 2008 (39 months 
after the first intervention), second operative procedure was made with subtotal excision of the tumor. 
No additional neurological deficit developed after the procedure. In April 2009 (44 months after the 
initial diagnosis), the patient is still alive with moderate neurological deficit. We made microarray 
analysis of the tumor using genomic array CytoChip and BlueFuse 3.5 software 
(http://www.cytochip.com/cytochip) [1]. The following numeric chromosomal aberrations were found: 
monosomy 8, 10, 13, 22, and trisomy 21, as well as amplifications in 4q34.1, 4q28.2, 6q16.3, 7q36.1, 
7p21.3, and deletions in 1q42.12, 1q32.2, 1q25.2, 1p33, 2q37.2, 18q22.3, 19p13.2, Xq28, and Xq27.3 
(fig. 3). 
Discussion 
Glioblastoma (WHO grade IV glioma) is the most common and most aggressive of all 
primary brain tumors. Despite multimodal treatment approaches, overall survival is less 
than a year in most of the cases. However, individual survival varies between patients. 
Those who survive ≥3 years after the initial diagnosis are defined as long-term survivors 
(LTSs). The LTSs account for 2–5% of all cases having GBM [2–7]. 
According to Shinojima et al. (2004), young age at presentation and female gender are 
both predictors for long-term survival in cases with GBM. The authors describe 6 cases of 
GBM patients with a survival of more than 5 years. All 6 were women, with a mean age of 
44.2 years [8].
 On the contrary, McLendon and Halperin (2003) found a different sex 
distribution. In a study of 17 LTSs with GBM, 11 were male and 6 female. The average age 
in the studied group was 40.2 years [6]. No socioeconomic, environmental and 
occupational factors were associated with the survival in a study on over 55 LTSs with 
GBM [7]. 
Scott et al. (1998) studied a population of 279 patients with histologically confirmed 
GBM. Five (1.8%) were classified as LTSs (survival range 3.2–15.8 years). Seven LTSs who 
were initially classified as GBM patients were excluded after neuropathological 
reevaluation [9]. The need of histological confirmation in LTSs was clearly demonstrated 
by Kraus and colleagues (2000) [4]. The authors found that 25% (13/52) of the patients  
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initially diagnosed as LTSs were actually mistaken, mostly with anaplastic 
oligodendroglioma (7), anaplastic oligoastrocytoma (2), anaplastic astrocytoma (3), and 
anaplastic pilocytic astrocytoma (1) [4]. In 2003, McLendon and Halperin (2003) found 
that from 32 LTSs initially diagnosed as GBMs, only 17 covered the WHO criteria for 
grade IV glioma. The authors assumed that intermediate fibrillary elements were more 
common and small anaplastic elements were less common in LTSs [6]. Shinojima et al. 
(2004) found giant cell elements on histopathological studies exclusively in long-term 
survival cases with GBM [8]. Deb and colleagues (2005) investigated 6 long-term survival 
GBM patients (mean age 9 years, range 5–15). In 3 of them histology was typical, in 2 an 
oligodendroglial component was present, and in 1 giant cells were identified [10]. The 
clinical presentation of GBM in LTSs may include headache, nausea and vomiting, 
seizures, visual disturbances, focal neurological deficits, and cognitive dysfunction. 
According to some authors, a longer duration of signs and symptoms prior to diagnosis is 
more likely to be found in LTSs than in short-term survivors (STSs): 52 versus 7.2 weeks 
[9]. The high Karnofsky Performance Scale (KPS) score at time of diagnosis is a well-
defined predictor for prolonged survival in the cases having GBM [8, 9, 11, 12]. 
MRI is the diagnostic tool of choice for preoperative evaluation of the patients with 
primary brain tumors. Glioblastomas usually appear as a ring-enhancing lesion with 
central hypodense core observed on T1-weighted images and a broad surrounding zone 
of edema apparent on T2-weighted images. At the present time, it is not possible to 
recognize which patient will become a LTS on the basis of neuroimaging. Mut and co-
workers (2007) looked for possible correlations between neuroimaging characteristics and 
p53 expression in 85 GBM patients. There was no correlation between tumor location, 
dimension of enhancing lesion, surrounding edema, mass effect, and tumor necrosis and 
level of p53 expression. A group of GBMs having >50% p53 expression had ring-
enhancement pattern and well-defined border on MRI, and they were significantly 
different from the other p53 subgroups [13]. 
Treatment approaches in cases with GBM include surgery followed by radio- and 
chemotherapy. The aim of surgical intervention is to achieve maximal tumor excision 
with no or with minimal patient deterioration [3, 5, 8, 14]. The gross-total tumor removal 
seems not to be essential for long-term survival in GBM patients. Investigating 22 LTSs 
with GBM, Chandler and co-workers (1993) found gross-total excision in 2 and subtotal 
resection in 20 cases [2]. In a study on 17 LTSs, McLendon and Halperin (2003) found 
gross-total tumor removal in 4 and subtotal resection in 10 cases. Biopsy was performed 
in one, and unknown tumor resection in 2 cases [6]. Radiotherapy in combination with 
chemotherapy is defined as the gold standard in the treatment of adult patients with 
GBM. The standard regimen includes fractionated focal irradiation in daily fractions of 
2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy, and continuous daily 
temozolomide (75 mg per
 m
2 of body-surface area per day, 7 days per week from
 the first 
to the last day of radiotherapy), followed by 6
 cycles of adjuvant temozolomide (150 to 
200 mg per m
2 for 5 days during each 28-day cycle) [15]. Most authors agree that a more 
aggressive multimodal therapeutic approach is associated with prolonged survival [3, 12, 
15]. Interestingly, in 2001, Sabel et al. described a 69-year-old LTS patient with giant cell 
GBM who had not undergone postoperative radiotherapy or adjuvant chemotherapy. The 
patient died from unrelated oncologic disease without data for local GBM recurrence 
[16]. 
The length of the disease-free period is strongly associated with the patient’s overall 
survival, suggesting that some grade IV gliomas follow a quicker course, with others 
exhibiting slow growth [2, 9, 12, 17]. The need for a second operation in cases with  
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recurrent GBM is disputed. According to Pinsker and Lumenta (2001), prolongation of 
survival time after reoperation was statistically significant only in the subgroup of patients 
with a KPS score of ≥90 [18].
 Filippini et al. (2008) published a study with 676 patients 
with primary GBM. In 25.0% of them, reoperation was performed but had no impact on 
patients’ overall survival [12]. 
Routine histopathological grading has limited capacity to predict survival of patients 
with GBM [19–21]. Currently, efforts are focused on detecting molecular predictors for 
GBM survival. Genetic studies show that GBMs consist of several genetic subtypes. The 
most common genetic alteration is chromosome 10 deletions, especially loss of 
MMAC/PTEN locus [22]. According to Ushio et al. (2003), PTEN alterations represent a 
significant unfavorable prognostic factor in the cases having GBM [23]. In 2000, Schiebe 
and co-workers [24] studied both mdm2 and p53 gene alterations in 75 GBM patients. 
They found that p53 mutation is associated with younger age and prolonged survival, 
while mdm2 amplification correlated with worse prognosis. In 2002, Burton and 
colleagues [25] compared p53 aberrations (expression/mutation), EGFR overexpression, 
mdm2 overexpression, and proliferation index in 41 LTSs and 48 STSs. The data suggest 
that LTSs were more likely to be associated with p53-overexpression, although a 
statistically significant difference in p53 mutation rate could not be detected. LTSs were 
less likely to exhibit mdm2 overexpression and showed a lower proliferation rate 
compared with STSs. Another study of 39 LTSs and 24 STSs found that 19q loss correlates 
with long-term survival. Multivariate analysis indicated that presentation of 2 or more of 
the following alterations is associated with short-term survival (p < 0.01): 6q loss, 10q loss, 
and 19q gain [26]. Nigro et al. (2005) studied 34 cases with GBM using microarray CGH 
and array-based gene expression profiling to identify relationships between gene copy 
number, gene expression levels, and survival. The loss of chromosome 10 was associated 
with genome-wide differences in gene expression. The authors found that CHI3L1/YKL-
40 (1q32.1) was associated with chromosome 10 loss and poorer survival [27]. Epidermal 
growth factor receptor (EGFR) expression was not detected in any of the long-term 
survival cases described by Deb and colleagues [10] in 2005. The authors found p53 
expression in 4 out of 5 studied patients [10]. In 2005, Korshunov et al. [28] investigated 
189 ‘young adult’ patients (<50 years). The survival was shorter in the cases having EGFR 
amplification and loss of 9p. In contrast, patients having gain of chromosome 9 had more 
favorable outcome. Later, the same authors described 46 copy number aberrations 
(CNAs) strongly associated with outcome in GBM patients. Using array-based 
comparative genomic hybridization (CGH) analysis in 70 GBM cases, they found 26 
CNAs associated with STSs, and 20 with LTSs [29]. Houillier et al. (2006) investigated 220 
primary GBM patients with the aim of predicting molecular factors. Limited impact was 
observed only in accordance with MDM2 amplification which was found to be a poor 
prognostic factor (p = 0.01) [11]. Krex and co-workers (2007) analyzed a group of 55 
LTSs. The molecular analyses revealed MGMT hypermethylation in 28 of 36 investigated 
tumours (74%). TP53 mutations were found in 9 of 31 cases (29%) and EGFR 
amplification in 10 of 38 cases (26%). Only 2 of 32 cases (6%) carried a combined 1p and 
19q deletion [7]. Hau et al. (2007) confirmed that MGMT promoter methylation is a 
valuable molecular diagnostic tool to predict GBM response to chemoradiation [30]. In 
2008, Marko and co-workers studied 7 GBM patients with more than 24 months and 13 
with less than 9 months of survival. The authors used a gene-expression analysis and 
prospective mathematical classification algorithm to stratify unknown GBMs. They found 
43 ‘fingerprint’ genes distinguishing different phenotypes and assumed that unique 
expression profiles characterize genotypic subsets of GBM associated with patient survival 
[31].  
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Conclusion 
GBMs seem to be a heterogenous group of glial tumors with different clinical course 
and therapeutic response. The microarray analysis is a useful method to establish a 
number of possible molecular predictors. 
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Fig. 1. MRI images of the patient before initial surgical procedure in August 2005 (on the left), five 
months later (middle), and before the second operative intervention in December 2008 (on the right). 
 
 
 
Fig. 2. Routine histological investigation of the tumor after first (on the left, H&E ×250) and second (on 
the right, H&E ×100) operative interventions. Significant number of bizarre, multinucleated giant cells 
as well as marked cellularity, hyperchromatism, pleomorphism, prominent neovascularization, and 
areas of pseudopalisading necrosis were present on both tumor samples. 
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Fig. 3. The microarray analysis of the tumor obtained during the second operative intervention 
demonstrated monosomy 8, 10, 13, 22, and trisomy 21, as well as amplifications in 4q34.1, 4q28.2, 
6q16.3, 7q36.1, 7p21.3, and deletions in 1q42.12, 1q32.2, 1q25.2, 1p33, 2q37.2, 18q22.3, 19p13.2, Xq28, 
and Xq27.3. 
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